{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/venous-eczema-lipodermatosclerosis/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"6fd54eff-ede5-5162-be02-2b8cdd28af3a","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 49aaafc8-adae-4ed2-957e-7c4f4cedb56e --><h2>How should I assess the person?</h2><!-- end field 49aaafc8-adae-4ed2-957e-7c4f4cedb56e -->","summary":"","htmlStringContent":"<!-- begin item a475f274-88b4-4127-9103-d0f6a379ba56 --><!-- begin field a11e0aab-2781-4376-8c75-e44269ac51ca --><ul><li><strong>Take a history. </strong><ul><li>Ask about other symptoms of venous insufficiency, such as pain, heaviness, aching, swelling, and itching of the affected leg. Symptoms are typically worse at the end of the day and are relieved by leg elevation. </li><li>Identify <a class=\"topic-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/background-information/causes-risk-factors/\">risk factors</a> for venous insufficiency, such as immobility and previous history of deep vein thrombosis (DVT).</li></ul></li><li><strong>Examine the person.</strong><ul><li>Assess and document the nature and severity of skin changes. Venous skin changes usually occur on the lower legs and are often bilateral. They vary from hyperpigmentation, to venous eczema, to lipodermatosclerosis and atrophie blanche. <ul><li><strong>Hyperpigmentation </strong>(brown-red colour) results from haemosiderin deposition as red blood cells extravasate into the surrounding tissue. </li><li><strong>Venous eczema</strong> is characterized by red, itchy, scaly, or flaky skin, which may have blisters and crusts on the surface. Pain and swelling may also be present. </li><li><strong>Lipodermatosclerosis</strong> (which may be acute or chronic) results from chronic inflammation and fibrosis of the dermis and subcutaneous tissue of the lower legs. </li><li><strong>Acute lipodermatosclerosis</strong> (sclerosing panniculitis) is characterized by painful inflammation above the ankles, which may be mistaken for cellulitis or phlebitis.</li><li><strong>Chronic lipodermatosclerosis</strong> may follow an acute episode or develop gradually. It is characterized by painful, hardened, tight, red or brown skin, which if circumferentially affecting the ankle area may eventually result in the leg having an 'inverted champagne bottle' or 'bowling pin' appearance. </li><li><strong>Atrophie blanche</strong> (star-shaped, ivory white, depressed, atrophic scars with surrounding pigmentation) may be seen in severe cases. </li></ul></li><li>Examine the legs for other signs of venous insufficiency, including:<ul><li>Varicose veins — examine the person standing and lying, and document the location and severity of any varicose veins. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/varicose-veins/\">Varicose veins</a> for more information.</li><li>Pitting oedema — exclude non-venous causes of oedema, such as heart failure and chronic kidney disease. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li></ul></li><li>Assess for <a class=\"topic-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/background-information/complications/\">complications</a> of venous skin changes, such as infection and leg ulceration. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/leg-ulcer-venous/\">Leg ulcer - venous</a> for more information.</li></ul></li></ul><!-- end field a11e0aab-2781-4376-8c75-e44269ac51ca --><!-- end item a475f274-88b4-4127-9103-d0f6a379ba56 -->","topic":{"id":"a90d58ca-80ba-5e1b-aee1-810e3e75187f","topicId":"ea8f06ec-40eb-41f8-9dfd-55c794f27eef","topicName":"Venous eczema and lipodermatosclerosis","slug":"venous-eczema-lipodermatosclerosis","lastRevised":"Last revised in February 2020","chapters":[{"id":"dde62ebe-397a-5a97-a6cc-5be3e33cc5af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c68bfeb8-9972-534c-9530-889987cb5449","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3289083a-63ae-5da0-ac55-7573b0b17e80","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0c543bca-830a-534b-8081-93b33f8b85c4","slug":"changes","fullItemName":"Changes"},{"id":"48b87d07-a723-5292-9ace-293d9160cdc4","slug":"update","fullItemName":"Update"}]},{"id":"26fa0abb-6866-5692-acab-9ac97d7377a2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"759b466b-d727-585b-b067-bd85aa0ff065","slug":"goals","fullItemName":"Goals"},{"id":"df4ffd20-23d7-5bf7-88d8-e064628216cc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"432518ea-af23-5e82-9821-0e3b3f64d100","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"61c73dfb-a783-5b00-909e-2cae0b88464a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e063dd9a-672b-5aed-8195-115ff345b93c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ee243c9c-f990-522c-8ece-834e1a1625ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a3b857fc-5924-5943-a8ff-aa8801577fd9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2b743c8-8392-5dd2-b5e2-7164cadb1027","slug":"definition","fullItemName":"Definition"},{"id":"7317d644-d2ef-5ab1-8752-8210b1dd55aa","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"f11ac6ce-bfa7-52f0-9949-0450b1dee13a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7c8938f1-30fe-5d79-beb8-bdf649b87db2","slug":"complications","fullItemName":"Complications"},{"id":"c3d84936-e709-5cdb-9f0a-62f8b60ba832","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"e08ced9c-b342-5444-8be4-fe70ab51e86c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6fd54eff-ede5-5162-be02-2b8cdd28af3a","slug":"assessment","fullItemName":"Assessment"}]},{"id":"e758669a-dc76-5648-baa4-05ae63eb3540","fullItemName":"Management","slug":"management","subChapters":[{"id":"e59690b0-42ea-54b4-8382-b034ef6f16ce","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3f3a5c09-2fc5-59a4-a6cb-6aaffc55117c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a250fefd-c169-5b73-94f6-d46d48a160a7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bd8d70cc-8839-5f5a-93a6-e5a87374ebcc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"021e369a-1e49-5fe5-bd4a-f7af97404cdc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"87e6498d-2fdf-5fc7-8892-40e897a23461","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"78b755bf-f3ac-5b6a-9e94-9446b45d0828","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5d1768a-5976-5dc9-be51-3aded0ca00df","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a933531e-0f39-56c6-a0c2-95df36dab832","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e08ced9c-b342-5444-8be4-fe70ab51e86c","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"8af3596c-a54f-5185-a01a-2d83a92cd622","slug":"basis-for-recommendation-426","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 4196171d-1b66-4c49-9a34-a7620159de0e --><h3>Basis for recommendation</h3><!-- end field 4196171d-1b66-4c49-9a34-a7620159de0e -->","summary":null,"htmlStringContent":"<!-- begin item 4268792e-a9d3-407a-b74e-a7620159df25 --><!-- begin field e3b801ae-033b-43f5-ad59-a7620159de0e --><p>These recommendations and the clinical features of venous skin changes are largely based on expert opinion in the Primary Care Dermatology Society (PCDS) guidelines <em>Lipodermatosclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2015</a>] and <em>Eczema: gravitational eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>], review articles on venous skin changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Quartey-Papafio, 1999</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">White and Ryjewski, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Barron et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Middleton, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">DermNet NZ, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">McVittie, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">DermNet NZ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Sundaresan, 2017</a>], and the British Association of Dermatologists (BAD) Patient Information Leaflet on <em>Venous eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">BAD, 2016</a>].</p><p> </p><!-- end field e3b801ae-033b-43f5-ad59-a7620159de0e --><!-- end item 4268792e-a9d3-407a-b74e-a7620159df25 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}